Alan Lader
Director Técnico/Científico/I+D en CITIUS PHARMACEUTICALS, INC. .
Perfil
Alan Lader is currently the SVP, Head-Clinical Operations & Quality Assurance at Citius Pharmaceuticals, Inc. Previously, he worked as the Director-Clinical Operations at Ischemix, Inc. Lader received his undergraduate degree from Syracuse University, his graduate degree from Rensselaer Polytechnic Institute, and his doctorate from the University of South Carolina School of Medicine.
Cargos activos de Alan Lader
| Empresas | Cargo | Inicio |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/03/2016 |
Antiguos cargos conocidos de Alan Lader.
| Empresas | Cargo | Fin |
|---|---|---|
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Formación de Alan Lader.
| University of South Carolina School of Medicine | Doctorate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
| Syracuse University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Bolsa de valores
- Insiders
- Alan Lader